264 related articles for article (PubMed ID: 26354773)
1. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and genomic features of gliosarcomas.
Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH
J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
[TBL] [Abstract][Full Text] [Related]
3. Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
Vuong HG; Dunn IF
J Neurooncol; 2022 Aug; 159(1):195-200. PubMed ID: 35768633
[TBL] [Abstract][Full Text] [Related]
4. Clinical and survival characteristics of primary and secondary gliosarcoma patients.
Amer A; Khose S; Alhasan H; Pokhylevych H; Fuller G; Chasen N; de Groot J; Johnson JM
Clin Neurol Neurosurg; 2022 Mar; 214():107146. PubMed ID: 35101778
[TBL] [Abstract][Full Text] [Related]
5. Gliosarcoma. A study of 13 tumors, including p53 and CD34 immunohistochemistry.
Sreenan JJ; Prayson RA
Arch Pathol Lab Med; 1997 Feb; 121(2):129-33. PubMed ID: 9126039
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
[TBL] [Abstract][Full Text] [Related]
7. Gliosarcomas with the
Wang L; Sun J; Li Z; Chen L; Fu Y; Zhao L; Liu L; Wei Y; Teng L; Lu D
J Clin Pathol; 2017 Dec; 70(12):1079-1083. PubMed ID: 28775171
[TBL] [Abstract][Full Text] [Related]
8. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
9. An IDH1-mutated primary gliosarcoma: case report.
Hsieh JK; Hong CS; Manjila S; Cohen ML; Lo S; Rogers L; Sloan AE
J Neurosurg; 2017 Feb; 126(2):476-480. PubMed ID: 27153165
[TBL] [Abstract][Full Text] [Related]
10. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
11. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
Rodriguez FJ; Scheithauer BW; Jenkins R; Burger PC; Rudzinskiy P; Vlodavsky E; Schooley A; Landolfi J
Am J Surg Pathol; 2007 Mar; 31(3):351-62. PubMed ID: 17325476
[TBL] [Abstract][Full Text] [Related]
12. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.
Damodaran O; van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G
J Clin Neurosci; 2014 Mar; 21(3):478-81. PubMed ID: 24332268
[TBL] [Abstract][Full Text] [Related]
13. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.
Oh JE; Ohta T; Nonoguchi N; Satomi K; Capper D; Pierscianek D; Sure U; Vital A; Paulus W; Mittelbronn M; Antonelli M; Kleihues P; Giangaspero F; Ohgaki H
Brain Pathol; 2016 Jul; 26(4):517-22. PubMed ID: 26443480
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
[TBL] [Abstract][Full Text] [Related]
15. Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma.
Nagaishi M; Kim YH; Mittelbronn M; Giangaspero F; Paulus W; Brokinkel B; Vital A; Tanaka Y; Nakazato Y; Legras-Lachuer C; Lachuer J; Ohgaki H
Am J Pathol; 2012 May; 180(5):1816-23. PubMed ID: 22538188
[TBL] [Abstract][Full Text] [Related]
16. Gliosarcoma: Neuroimaging and Immunohistochemical Findings.
Peckham ME; Osborn AG; Palmer CA; Tsai A; Salzman KL
J Neuroimaging; 2019 Jan; 29(1):126-132. PubMed ID: 30295979
[TBL] [Abstract][Full Text] [Related]
17. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components.
Actor B; Cobbers JM; Büschges R; Wolter M; Knobbe CB; Lichter P; Reifenberger G; Weber RG
Genes Chromosomes Cancer; 2002 Aug; 34(4):416-27. PubMed ID: 12112531
[TBL] [Abstract][Full Text] [Related]
19. Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature.
Din NU; Ishtiaq H; Rahim S; Abdul-Ghafar J; Ahmad Z
BMC Pediatr; 2021 Feb; 21(1):101. PubMed ID: 33637068
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Cho SY; Park C; Na D; Han JY; Lee J; Park OK; Zhang C; Sung CO; Moon HE; Kim Y; Kim JH; Kim JJ; Khang SK; Nam DH; Choi JW; Suh YL; Kim DG; Park SH; Youn H; Yun K; Kim JI; Lee C; Paek SH; Park H
Exp Mol Med; 2017 Apr; 49(4):e317. PubMed ID: 28408749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
